
Understanding of the immune response following COVID-19 vaccination in pregnancy is limited by small cohort size and little data on neutralizing antibodies. This was a prospective cohort study comprising patients with PCR-confirmed SARS-CoV-2 infection and patients who received both doses of mRNA COVID-19 vaccine (mRNA-1273, BNT162b2) in pregnancy recruited from two hospitals in Atlanta, Georgia, USA. There was a significant linear decline in maternal and cord blood RBD-IgG and neutralizing antibody titers as the time from vaccination to delivery increased. Those who receive the mRNA COVID-19 vaccine mount an immune response that is equivalent to – if not greater than- those naturally infected by SARS-CoV-2 during pregnancy.
Like
Save
Share